fluoxetine has been researched along with Lymphoma, B-Cell in 3 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
Lymphoma, B-Cell: A group of heterogeneous lymphoid tumors generally expressing one or more B-cell antigens or representing malignant transformations of B-lymphocytes.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We report a patient who developed lymphocytoma cutis temporally associated with initiation of fluoxetine therapy that later went on to develop cutaneous marginal zone B-cell lymphoma." | 7.73 | Cutaneous marginal zone B-cell lymphoma in the setting of fluoxetine therapy: a hypothesis regarding pathogenesis based on in vitro suppression of T-cell-proliferative response. ( Breza, TS; Magro, CM; Porcu, P; Zheng, P, 2006) |
| " We report a patient who developed lymphocytoma cutis temporally associated with initiation of fluoxetine therapy that later went on to develop cutaneous marginal zone B-cell lymphoma." | 3.73 | Cutaneous marginal zone B-cell lymphoma in the setting of fluoxetine therapy: a hypothesis regarding pathogenesis based on in vitro suppression of T-cell-proliferative response. ( Breza, TS; Magro, CM; Porcu, P; Zheng, P, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chamba, A | 2 |
| Holder, MJ | 2 |
| Jarrett, RF | 1 |
| Shield, L | 1 |
| Toellner, KM | 1 |
| Drayson, MT | 2 |
| Barnes, NM | 2 |
| Gordon, J | 2 |
| Meredith, EJ | 1 |
| Challa, A | 1 |
| Drake-Lee, A | 1 |
| Bunce, CM | 1 |
| Pilkington, G | 1 |
| Blakely, RD | 1 |
| Dyer, MJ | 1 |
| Breza, TS | 1 |
| Zheng, P | 1 |
| Porcu, P | 1 |
| Magro, CM | 1 |
3 other studies available for fluoxetine and Lymphoma, B-Cell
| Article | Year |
|---|---|
SLC6A4 expression and anti-proliferative responses to serotonin transporter ligands chlomipramine and fluoxetine in primary B-cell malignancies.
Topics: Animals; Cell Proliferation; Cells, Cultured; Clomipramine; Fluoxetine; Humans; L Cells; Lymphoma, B | 2010 |
The serotonin transporter (SLC6A4) is present in B-cell clones of diverse malignant origin: probing a potential anti-tumor target for psychotropics.
Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Burkitt L | 2005 |
Cutaneous marginal zone B-cell lymphoma in the setting of fluoxetine therapy: a hypothesis regarding pathogenesis based on in vitro suppression of T-cell-proliferative response.
Topics: Anticonvulsants; Antidepressive Agents, Second-Generation; Bupropion; Cells, Cultured; Dose-Response | 2006 |